Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE-201: AHB-137 in HBeAg Negative Chronic Hepatitis B
NCT07370207Phase 2Recruiting
- Sponsor
- AusperBio
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 7
01
Overview
A Phase 2 trial of AHB-137 in Chronic Hepatitis B (CHB), sponsored by AusperBio. Started Mar 2026; status: recruiting.
02
Drugs
AHB-137
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07370207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07370207.